6h
Zacks.com on MSNAxsome Stock Surges 20% on Auvelity Patent Settlement With TevaAXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...
BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares ...
TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company ...
UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...
Axsome Therapeutics (NASDAQ:AXSM) received a reiterated Buy rating and a $190.00 price target from H.C. Wainwright, representing significant upside from the current price of $127.08. The stock has ...
Despite resilient consumer demand for Coca-Cola products, a strong dollar could bring down the firm’s financial results as it ...
Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results